Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Other Working Capital Changes (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Other Working Capital Changes for 15 consecutive years, with $27.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes fell 2.46% year-over-year to $27.8 million, compared with a TTM value of $44.4 million through Dec 2025, down 17.78%, and an annual FY2025 reading of $44.4 million, down 17.78% over the prior year.
  • Other Working Capital Changes was $27.8 million for Q4 2025 at Neurocrine Biosciences, down from $42.1 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $42.1 million in Q3 2025 and bottomed at -$23.0 million in Q2 2025.
  • Average Other Working Capital Changes over 4 years is $7.5 million, with a median of -$100000.0 recorded in 2023.
  • Peak annual rise in Other Working Capital Changes hit 8600.0% in 2024, while the deepest fall reached 1600.0% in 2024.
  • Year by year, Other Working Capital Changes stood at -$1.7 million in 2021, then soared by 176.47% to $1.3 million in 2023, then skyrocketed by 2092.31% to $28.5 million in 2024, then decreased by 2.46% to $27.8 million in 2025.
  • Business Quant data shows Other Working Capital Changes for NBIX at $27.8 million in Q4 2025, $42.1 million in Q3 2025, and -$23.0 million in Q2 2025.